Results 21 to 30 of about 2,540 (169)
Inclisiran: First Approval [PDF]
Drugs, 2021 Inclisiran (Leqvio®; Novartis) is a first-in-class, cholesterol-lowering small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates (GalNAc). Inclisiran received its first approval in December 2020 in the EU for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed ...
openaire +2 more sources
American Journal of Preventive Cardiology, 2023 Therapeutic Area: ASCVD/CVD Risk Factors Background: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C lowering agent ...
Lawrence A Leiter +9 more
doaj +1 more source
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia [PDF]
New England Journal of Medicine, 2020 Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but ...
Raal, Frederick J. +11 more
openaire +4 more sources
American Heart Journal Plus, 2022 Study objective: This systematic review and meta-analysis aimed to assess the efficacy and safety profile of treatment with inclisiran, a drug that has been recently approved by the United States Food and Drug Administration (FDA) and the European ...
Arrigo F.G. Cicero +4 more
doaj +1 more source
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
Pharmaceuticals, 2023 Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a novel lipid-lowering drug category has emerged, i.e.,
Niki Katsiki +3 more
doaj +1 more source
Cardiovascular Therapeutics, 2022 As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide.
Iveta Merćep +3 more
doaj +1 more source
American Journal of Preventive Cardiology, 2023 Therapeutic Area: CVD Prevention – Primary and Secondary Background: Patients are at high risk for a recurrent cardiovascular (CV) event in the first year following acute coronary syndrome (ACS).
Jeffrey L. Anderson, MD +4 more
doaj +1 more source
Inclisiran - hope in the fight against dyslipidemia
Journal of Education, Health and Sport, 2023 Introduction:Lipid disorders are one of the most common modifiable risk factors for cardiovascular disease. Until now, the mainstay of dyslipidemia treatment was the use of widely available statins.
Paulina Krawiec +9 more
doaj +1 more source
Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis [PDF]
Journal of Clinical Medicine, 2021 The reduction of circulating low-density lipoprotein-cholesterol (LDL-C) is a primary target in cardiovascular risk reduction due to its well-established benefits in terms of decreased mortality. Despite the use of statin therapy, 10%–20% of high- and very-high-risk patients do not reach their LDL-C targets.
Sylwester Rogula +6 more
openaire +2 more sources
Canadian Journal of Health Technologies, 2022 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +2 more sources